X4 Pharmaceuticals (XFOR) Gets a Buy from Piper Sandler

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on X4 Pharmaceuticals (XFOR – Research Report), with a price target of $3.00. The company’s shares closed yesterday at $1.09.

According to TipRanks, Tenthoff is an analyst with an average return of -0.9% and a 34.62% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Opko Health, and Cue Biopharma.

X4 Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $4.33, a 297.25% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $5.00 price target.

Based on X4 Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $49 thousand and a GAAP net loss of $19.13 million. In comparison, last year the company earned a revenue of $49 thousand and had a GAAP net loss of $29.1 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

X4 Pharmaceuticals (XFOR) Company Description:

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Cambridge, MA.